Transplant News and Research RSS Feed - Transplant News and Research

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics, Inc. announces the receipt of a Phase II SBIR grant in the amount of $1.54 million dollars from the U.S. National Institutes of Health to advance its novel Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry program. [More]
Americord Registry, Smart Cells International partner to educate parents on benefits of cord blood banking

Americord Registry, Smart Cells International partner to educate parents on benefits of cord blood banking

Today, Americord Registry announced a new partnership with Smart Cells International, the first cord blood company in the United Kingdom, as part of its initiatives during Cord Blood Awareness Month (July) to educate parents around the globe on the benefits of cord blood banking. [More]
Experimental new treatment approach can send deadly leukemia into remission

Experimental new treatment approach can send deadly leukemia into remission

An experimental new treatment approach for a rare, deadly leukemia can send the disease into remission even in patients for whom the standard therapy has failed, buying them more time to have the stem cell transplant that could save their lives, a small pilot study has found. [More]
University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

University of Pittsburgh surgeon receives Anthony Cerami Award in Translational Medicine

The Feinstein Institute for Medical Research and Molecular Medicine announced today that the fourth Anthony Cerami Award in Translational Medicine will be conferred to Thomas E. Starzl, MD, PhD, professor of surgery at the University of Pittsburgh School of Medicine. The award is in recognition of his research in organ transplantation and alloengraftment mechanisms. [More]
Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers have successfully used bone marrow-derived mesenchymal stromal cells (MSCs) to treat a variety of diseases and conditions. Now, using injections of MSCs, a research team in Brazil has successfully treated laboratory rats modeled with severe burns. [More]
New research could help reverse side effects of acetaminophen overdose

New research could help reverse side effects of acetaminophen overdose

New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines. [More]
DC Devices announces completion of enrollment in REDUCE LAP-HF trial for diastolic heart failure treatment

DC Devices announces completion of enrollment in REDUCE LAP-HF trial for diastolic heart failure treatment

DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices for heart failure, today announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD) – the world's first transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF). [More]
International researchers identify previously unknown genetic immunodeficiency

International researchers identify previously unknown genetic immunodeficiency

An analysis of five families has revealed a previously unknown genetic immunodeficiency, says an international team led by researchers from Boston Children's Hospital. The condition, linked to mutations in a gene called DOCK2, deactivates many features of the immune system and leaves affected children open to a unique pattern of aggressive, potentially fatal infections early in life. [More]
New tissue 'scaffold' technology could one day help produce large organs

New tissue 'scaffold' technology could one day help produce large organs

Scientists have developed a new tissue 'scaffold' technology that could one day enable the engineering of large organs. Research led by the Universities of Bristol and Liverpool has shown that it is possible to combine cells with a special scaffold to produce living tissue in the laboratory. It is hoped this can then be implanted into patients as a way of replacing diseased parts of the body. [More]

Loyola patient celebrates 10th anniversary of heart and double-lung transplant

On March 20, Andrew Gaumer celebrated the 10th anniversary of his life-saving heart and double-lung transplant. On Mother's Day, his wife, Andrea, gave birth to their first child, a baby boy named Jude. And on June 21, Andrew will celebrate his first Father's Day - a milestone he once feared he would never see. [More]
Rapamycin drug reduces obesity, preserves lean body mass in older rats

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Aging can cause many changes to the body, including obesity and a loss of lean mass. Now, a group of University of Florida Health researchers has discovered that an existing drug reduces body fat and appetite in older rats, which has intriguing implications for aging humans. [More]
Women who underwent uterine transplantation adjust to sudden restoration of fertility

Women who underwent uterine transplantation adjust to sudden restoration of fertility

In October last year the Gothenburg, Sweden, group of Mats Bra?nnstro?m announced the world's first live birth following the transplantation of a donated uterus. [More]
FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure. [More]
Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic, United Therapeutics partner to build and operate new lung restoration center on Mayo campus

Mayo Clinic in Jacksonville, Fla., and United Therapeutics Corporation today announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States. [More]
SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenXTM-1000 System and the CryoPRO Workstation to process its umbilical cord blood units. Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.’s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015. [More]
Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). [More]
Researchers show how a new drug speeds tissue regeneration in animal models

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality. [More]
Clinical support for kidney perfusion

Clinical support for kidney perfusion

Lifeline Scientific (AIM: LSIC), the transplantation technology company, welcomes the publication in Experimental and Clinical Transplantation of the clinical study (‘Study’): “Hypothermic Machine Perfusion Permits Extended Cold Ischemia Times With Improved Early Graft Function.” [More]
A gastroenterologist guide to probiotics

A gastroenterologist guide to probiotics

In recent years, scientists have introduced us to a paradigm shift in the microscopic world. We've moved from thinking about all bacteria as bad guys to be wiped out with antibiotics and hand sanitizer to recognizing that some microbes are helpers, good bacteria that live in our GI tract (and all over our bodies) that keep us healthy. [More]
Researchers examine specific causes of mortality after blood and marrow transplant

Researchers examine specific causes of mortality after blood and marrow transplant

Blood and Marrow Transplantation (BMT) is a potentially curative treatment for patients with leukemia or other life-threating blood diseases. With a goal of increasing survival rates, a research team led by Roswell Park Cancer Institute investigators verified patient outcome data submitted by more than 150 U.S. transplant centers over an 11-year period to the Center for International Blood and Marrow Transplant Research. [More]
Advertisement
Advertisement